VYNE Therapeutics Inc. Common Stock
VYNEVYNE Therapeutics Inc. is a biopharmaceutical company focused on developing innovative, prescription-based therapies for dermatologic conditions. Founded with the goal of addressing underserved skin diseases, VYNE leverages proprietary formulations and technologies to create targeted treatments. The company’s portfolio includes products aimed at conditions such as atopic dermatitis and other inflammatory skin disorders.
Company News
Monteverde & Associates PC, a class action securities firm, is investigating four merger and acquisition transactions: VYNE Therapeutics' merger with Yarrow Bioscience (VYNE shareholders to own 3% of combined company), Masimo Corporation's sale to Danaher ($180 per share), Independent Bank Corporation's sale to HCB Financial Corp, and HCB Financi...
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to merger and acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.
VYNE Therapeutics and Yarrow Bioscience have agreed to merge in an all-stock transaction, with Yarrow becoming the combined company. The merger will focus on advancing YB-101, a potential first-in-class antibody for treating Graves' disease and thyroid eye disease, supported by approximately $200 million in pre-closing private financings.
Over 18 pharmaceutical companies are developing targeted therapies for vitiligo, with promising pipeline drugs showing potential to transform treatment options beyond conventional approaches like corticosteroids and phototherapy.
Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases
